USD 0.01
(0.0%)
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2023 | -4601.00 USD | -146.01% |
2022 | 10 Thousand USD | 0.0% |
2021 | - USD | 0.0% |
2020 | - USD | 0.0% |
2015 | - USD | 0.0% |
2014 | - USD | 0.0% |
2013 | - USD | 0.0% |
2012 | - USD | 0.0% |
2011 | - USD | 0.0% |
2010 | - USD | 0.0% |
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2023 FY | -4601.00 USD | -146.01% |
2023 Q4 | -1150.00 USD | 0.0% |
2023 Q3 | -1150.00 USD | 0.09% |
2023 Q2 | -1151.00 USD | -0.09% |
2023 Q1 | -1150.00 USD | 0.0% |
2022 Q4 | - USD | -100.0% |
2022 FY | 10 Thousand USD | 0.0% |
2022 Q1 | - USD | 0.0% |
2022 Q2 | - USD | 0.0% |
2022 Q3 | 10 Thousand USD | 0.0% |
2021 Q2 | - USD | 0.0% |
2021 Q4 | - USD | 0.0% |
2021 FY | - USD | 0.0% |
2021 Q3 | - USD | 0.0% |
2020 FY | - USD | 0.0% |
2015 Q3 | - USD | 0.0% |
2015 Q2 | - USD | 0.0% |
2015 Q1 | - USD | 0.0% |
2015 FY | - USD | 0.0% |
2015 Q4 | - USD | 0.0% |
2014 FY | - USD | 0.0% |
2014 Q4 | - USD | 0.0% |
2014 Q2 | - USD | 0.0% |
2014 Q1 | - USD | 0.0% |
2014 Q3 | - USD | 0.0% |
2013 Q1 | - USD | 0.0% |
2013 FY | - USD | 0.0% |
2013 Q3 | - USD | 0.0% |
2013 Q2 | - USD | 0.0% |
2013 Q4 | - USD | 0.0% |
2012 Q3 | - USD | 0.0% |
2012 Q4 | - USD | 0.0% |
2012 FY | - USD | 0.0% |
2012 Q1 | - USD | 0.0% |
2012 Q2 | - USD | 0.0% |
2011 Q1 | - USD | 0.0% |
2011 Q2 | - USD | 0.0% |
2011 Q3 | - USD | 0.0% |
2011 Q4 | - USD | 0.0% |
2011 FY | - USD | 0.0% |
2010 FY | - USD | 0.0% |
Name | Gross Profit | Gross Profit Difference |
---|---|---|
America Great Health | 168.58 Thousand USD | 102.729% |
Ampio Pharmaceuticals, Inc. | -250 Thousand USD | 98.16% |
Aridis Pharmaceuticals, Inc. | - USD | Infinity% |
Biora Therapeutics, Inc. | -551 Thousand USD | 99.165% |
Bio-Path Holdings, Inc. | -178 Thousand USD | 97.415% |
Better Therapeutics, Inc. | -2.72 Million USD | 99.831% |
Calithera Biosciences, Inc. | -1.38 Million USD | 99.668% |
Comera Life Sciences Holdings, Inc. | 422.71 Thousand USD | 101.088% |
Gene Biotherapeutics, Inc. | - USD | Infinity% |
eFFECTOR Therapeutics, Inc. | -22.91 Million USD | 99.98% |
Eloxx Pharmaceuticals, Inc. | - USD | Infinity% |
Evelo Biosciences, Inc. | - USD | Infinity% |
Evolutionary Genomics, Inc. | -1.02 Million USD | 99.55% |
Finch Therapeutics Group, Inc. | -7.09 Million USD | 99.935% |
Galera Therapeutics, Inc. | -259 Thousand USD | 98.224% |
Innovation1 Biotech Inc. | -52.69 Thousand USD | 91.269% |
Kiromic BioPharma, Inc. | -2.79 Million USD | 99.835% |
Molecular Templates, Inc. | 50.39 Million USD | 100.009% |
Navidea Biopharmaceuticals, Inc. | -119.29 Thousand USD | 96.143% |
NexImmune, Inc. | -1.02 Million USD | 99.551% |
Orgenesis Inc. | -5.72 Million USD | 99.92% |
Panbela Therapeutics, Inc. | -25.64 Million USD | 99.982% |
PaxMedica, Inc. Common Stock | - USD | Infinity% |
Scopus BioPharma Inc. | - USD | Infinity% |
Sorrento Therapeutics, Inc. | 29.38 Million USD | 100.016% |
Statera Biopharma, Inc. | -488.31 Thousand USD | 99.058% |
TRACON Pharmaceuticals, Inc. | -232 Thousand USD | 98.017% |
Trevena, Inc. | 1.45 Million USD | 100.316% |
Vaxxinity, Inc. | -2.23 Million USD | 99.794% |
Vaccinex, Inc. | -16 Million USD | 99.971% |
Vicapsys Life Sciences, Inc. | - USD | Infinity% |
Viracta Therapeutics, Inc. | -492 Thousand USD | 99.065% |
ZIVO Bioscience, Inc. | 11.61 Thousand USD | 139.63% |